Aug 14, 2026, 4:30 PM EDT · 7 weeks ago Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights
Jun 22, 2026, 7:00 AM EDT · 3 months ago Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program
2026-06-18T11:27:11.000Z · 3 months ago Traws Pharma downgraded to Neutral from Buy at H.C. Wainwright
2026-06-12T21:40:11.000Z · 3 months ago Traws Pharma influenza challenge study deferred following MHRA review
Jun 12, 2026, 5:30 PM EDT · 3 months ago Traws Pharma Provides Regulatory Update on Influenza Program
2026-05-27T13:04:01.000Z · 4 months ago Traws Pharma announces antiviral program targeting Hantavirus, Ebola
May 27, 2026, 8:45 AM EDT · 4 months ago Traws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks
May 15, 2026, 7:00 AM EDT · 4 months ago Traws Pharma Provides Business Highlights and Reports Q1 2026 Financial Results
2026-05-08T22:46:20.000Z · 5 months ago Traws Pharma files to sell 35.9M shares of common stock for holders
May 8, 2026, 1:43 PM EDT · 5 months ago There are no hantavirus treatments. The deadly cruise-ship outbreak is a ‘wake-up call' to develop some.
May 8, 2026, 7:30 AM EDT · 5 months ago Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections
Apr 15, 2026, 4:01 PM EDT · 5 months ago Traws Pharma Reports Full Year 2025 Results and Provides Business Highlights
2026-02-19T12:43:19.000Z · 7 months ago Traws Pharma completes clinical analysis of Phase 2 study of ratutrelvir
Feb 19, 2026, 7:30 AM EST · 7 months ago Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza
2026-01-26T13:35:09.000Z · 8 months ago Traws Pharma completes enrollment in Phase 2 study of ratutrelvir
2026-01-13T12:05:30.000Z · 8 months ago Traws Pharma files tivoxavir marboxil IND application with U.S. FDA
Jan 13, 2026, 7:00 AM EST · 8 months ago Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients
2025-12-17T11:11:13.000Z · 9 months ago Traws Pharma reports ‘positive’ interim data with ratutrelvir vs. paxlovid
Oct 30, 2025, 12:00 PM EDT · 11 months ago ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials
Oct 22, 2025, 6:40 PM EDT · 11 months ago Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19.
2025-10-14T11:10:48.000Z · 11 months ago Traws Pharma doses first patient with ratutrelvir in Phase 2 COVID studies
Oct 14, 2025, 7:00 AM EDT · 11 months ago Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025
2025-08-18T11:05:38.000Z · 1 year ago Traws Pharma receives approval to proceed with Phase 2 COVID studies
Aug 18, 2025, 7:00 AM EDT · 1 year ago Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025
Aug 14, 2025, 7:00 AM EDT · 1 year ago Traws Pharma Reports Second Quarter 2025 Results and Business Highlights
Aug 8, 2025, 7:00 AM EDT · 1 year ago Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025
Jun 30, 2025, 6:30 AM EDT · 1 year ago Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions
Jun 3, 2025, 7:00 AM EDT · 1 year ago Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib
May 27, 2025, 8:00 AM EDT · 1 year ago Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness
May 15, 2025, 7:00 AM EDT · 1 year ago Traws Pharma Reports First Quarter 2025 Results and Business Highlights
Mar 26, 2025, 7:30 AM EDT · 1 year ago Traws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ET
Mar 25, 2025, 7:30 AM EDT · 1 year ago Traws Pharma's COVID-19 Candidate, Ratutrelvir, Presented at ICAR
Mar 21, 2025, 7:00 AM EDT · 1 year ago Traws Pharma's Bird Flu Drug Candidate, Tivoxavir Marboxil, Presented at ICAR
Mar 3, 2025, 7:00 AM EST · 1 year ago Traws Pharma Reports Positive Results from An Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil
Feb 28, 2025, 7:00 AM EST · 1 year ago Traws Pharma Regains Compliance with NASDAQ Equity Listing Rule
Jan 23, 2025, 7:00 AM EST · 1 year ago Traws Pharma Announces Completion of Phase I Studies with Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird Flu
Jan 10, 2025, 5:55 PM EST · 1 year ago Expert Systems and Traws Pharma Report Breakthrough in H5N1Bird Flu Antiviral Program
Dec 30, 2024, 8:00 AM EST · 1 year ago Traws Pharma, Inc. Announces Financing up to $72.6 Million from Leading Healthcare Institutional Investors to Advance Tivoxavir Marboxil Development for H5N1 Bird Flu to Approval
Dec 23, 2024, 12:00 PM EST · 1 year ago Traws Pharma stock soars 200% on encouraging bird flu drug data
Dec 23, 2024, 7:00 AM EST · 1 year ago Traws Pharma Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu
Nov 14, 2024, 4:30 PM EST · 1 year ago Traws Pharma Provides Business Update and Reports Q3 2024 Financial Results
Oct 8, 2024, 7:30 AM EDT · 1 year ago Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil
Sep 30, 2024, 7:30 AM EDT · 2 years ago Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor
Sep 20, 2024, 7:30 AM EDT · 2 years ago Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors
Sep 17, 2024, 4:05 PM EDT · 2 years ago Traws Pharma, Inc. Announces Special Shareholders Meeting Results
Aug 15, 2024, 7:00 AM EDT · 2 years ago Traws Pharma Reports Q2 2024 Financial Results, Provides Recent Business Highlights
Aug 14, 2024, 4:30 PM EDT · 2 years ago Traws Pharma to Host Corporate Update Call on August 15, 2024, at 8:00 AM ET
Mar 8, 2024, 8:00 AM EST · 2 years ago Onconova Therapeutics' Rigosertib Poster Selected for AACR 2024 ONTX
Dec 8, 2023, 4:05 PM EST · 2 years ago Onconova Therapeutics' Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i's ONTX
Nov 28, 2023, 8:00 AM EST · 2 years ago Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets' Nineteenth Annual Emerging Growth Equity Conference ONTX
Nov 14, 2023, 4:05 PM EST · 2 years ago Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results ONTX
Nov 7, 2023, 4:05 PM EST · 2 years ago Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023 ONTX
Nov 2, 2023, 10:37 AM EDT · 2 years ago Onconova Therapeutics' ASH Poster To Focus on Narazaciclib in MCL ONTX
Oct 24, 2023, 8:00 AM EDT · 2 years ago Onconova Expands Leadership Team with Two Key Appointments ONTX
Oct 19, 2023, 8:00 AM EDT · 2 years ago Promising Preclinical Narazaciclib Data Presented at MCL Meeting ONTX
Sep 28, 2023, 8:00 AM EDT · 3 years ago Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV Congress ONTX
Sep 6, 2023, 8:00 AM EDT · 3 years ago Onconova Therapeutics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference ONTX
Jun 14, 2023, 8:00 AM EDT · 3 years ago Onconova Therapeutics Presents Preclinical Data on Narazaciclib at the 17th International Conference on Malignant Lymphoma ONTX